nimodipine has been researched along with Disease Models, Animal in 137 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "- We performed a systematic review of animal experiments with nimodipine in focal cerebral ischemia." | 8.81 | Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. ( de Haan, RJ; Horn, J; Limburg, M; Luiten, PG; Vermeulen, M, 2001) |
| " We propose a meta-analytical evaluation of published clinical trials on nimodipine, a dihydropiridin calcium antagonist, in subarachnoid hemorrhage and in ischemic stroke." | 8.79 | From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. ( Di Mascio, R; Marchioli, R; Tognoni, G, 1994) |
| "Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage." | 7.81 | Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. ( Ahtola-Sätilä, T; Forsback, AP; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Simola, O; Tarkia, M, 2015) |
| "We sought to explore whether topical administration of nimodipine improves the abnormal cerebral perfusion following subarachnoid hemorrhage (SAH) in pigs." | 7.79 | Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs. ( Jia, F; Jiang, JY; Wang, F; Yin, YH, 2013) |
| "Nimodipine improved outcome in patients with subarachnoid hemorrhage (SAH) although hypotension limited the dose that could be administered systemically." | 7.78 | Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. ( Ai, J; Cook, DJ; Kan, S; Kasuya, H; Macdonald, RL, 2012) |
| "the aim of this study was to assess and to compare the ability of intrathecal flunarizine and nimodipine to prevent vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 7.77 | Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. ( Civelek, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Secer, HI; Solmaz, I; Temiz, C, 2011) |
| "To explore the dose-response effects of topical administration of nimodipine on cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rabbits." | 7.75 | Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Jiang, JY; Luo, QZ; Pan, YH; Wang, F; Wang, Y; Yin, YH, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 7.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| " The aim of the present work was to assess the involvement of P-glycoprotein in carbamazepine and phenobarbital hippocampal pharmacokinetics in an experimental model of epilepsy, induced by repetitive MP administration." | 7.75 | Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ( Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009) |
| "This study was conducted to investigate the neuroprotective effects of 20(S)-ginsenoside Rg3 on focal cerebral ischemia in rats." | 7.73 | Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. ( Fu, F; Geng, M; Jiang, W; Jiang, Y; Liu, K; Tian, J; Wang, C; Yang, J, 2005) |
| "To compare the individual effects of baicalin and jasminoidin with the combined effect of them on cerebral ischemia-reperfusion injury, and test whether the combined administration of baicalin and jasminoidin can improve the therapeutic effect." | 7.73 | A comparative study on the individual and combined effects of baicalin and jasminoidin on focal cerebral ischemia-reperfusion injury. ( Li, P; Li, PT; Sun, ZH; Wang, YY; Wang, Z; Zhang, WS; Zhang, XJ; Zhang, ZJ, 2006) |
| "The present study evaluates the possible role of dihydropyridine calcium channel antagonist nimodipine on diclofenac analgesia in formalin-induced facial pain model in rats." | 7.72 | Potentiation of antihyperalgesic activity of diclofenac by nimodipine in a formalin model of facial pain in rats. ( Hota, D; Pandhi, P, 2004) |
| "The effect of nimodipine alone and in combination with diazepam or phenytoin was tested in the electroshock-induced mouse model of status epilepticus." | 7.70 | Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus. ( Khosla, P; Pandhi, P, 2000) |
| "Quinine ingestion reportedly induces tinnitus in humans." | 7.68 | Quinine-induced tinnitus in rats. ( Brennan, JF; Jastreboff, PJ; Sasaki, CT, 1991) |
| "A novel transient middle cerebral artery (MCA) occlusion model in the rat was used to evaluate the effect of nimodipine on brain edema and mortality." | 7.68 | Effect of nimodipine on ischemia-induced brain edema and mortality in a novel transient middle cerebral artery occlusion model. ( Hara, H; Kogure, K; Nagasawa, H; Onodera, H, 1990) |
| "The effects of nimodipine and thyrotropin-releasing hormone (TRH) were compared in a clip-compression model of experimental spinal cord injuries (SCI) in rats." | 7.68 | Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine. ( Aktürk, F; Baykal, S; Ceylan, S; Ilbay, K; Kalelioğlu, M; Komsuoğlu, SS; Ozmenoğlu, M; Ozoran, A; Sener, U, 1992) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 5.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| "Nimodipine treatment attenuated clinical EAE and spinal cord degeneration and promoted remyelination." | 5.46 | Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis. ( Ergün, S; Hell, JW; Jörg, S; Koeniger, T; Kuerten, S; Linker, RA; Schampel, A; Scholz, CJ; Volovitch, O; Wischmeyer, E; Wunsch, M, 2017) |
| "Human cerebral malaria (HCM) is a life-threatening complication caused by Plasmodium falciparum infection that continues to be a major global health problem despite optimal anti-malarial treatment." | 5.39 | Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria. ( Carvalho, LJ; Clemmer, L; Frangos, JA; Martins, YC; Ong, PK; Orjuela-Sánchez, P; Zanini, GM, 2013) |
| "Nimodipine is an effect-proven agent in CVS, but dotarizine may take place of it." | 5.37 | Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Solmaz, I; Tehli, O, 2011) |
| "Nimodipine treatment in cerebral vasospasm is useful." | 5.37 | Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Civelek, E; Isikay, I; Kircelli, A; Narin, F; Onal, MB; Solmaz, I; Ugurel, S; Yakupoglu, H, 2011) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 5.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "Traumatic subarachnoid hemorrhage is a common finding following traumatic brain injury." | 5.35 | Experimental subarachnoid hemorrhage in the rat: influences of nimodipine. ( Brinker, T; Herrmann, B; Samii, M; Thomas, S, 2008) |
| "One of the main limitations of intracerebral hemorrhage (ICH) research is lack of reproducible animal models." | 5.33 | Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. ( Ma, B; Zhang, J, 2006) |
| "Nimodipine-treated animals were then matched with vehicle-treated controls for both study conditions." | 5.32 | Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia. ( Burnett, MG; Gomi, S; Greenberg, JH; Karp, A, 2004) |
| "Reperfusion injury is a pathophysiological entity distinct from the primary ischaemic injury; the oxygen arriving with blood recirculation, although necessary for alleviating the ischaemic status, may be harmful and provoke additional injury in the already damaged tissue." | 5.29 | Can nimodipine prevent ischaemic reperfusion injury in the rat brain? ( Albariño, AR; Carceller, F; Díez-Tejedor, E; Gutiérrez-Molina, M; López-Pajares, R; Roda, JM, 1993) |
| "- We performed a systematic review of animal experiments with nimodipine in focal cerebral ischemia." | 4.81 | Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. ( de Haan, RJ; Horn, J; Limburg, M; Luiten, PG; Vermeulen, M, 2001) |
| " We propose a meta-analytical evaluation of published clinical trials on nimodipine, a dihydropiridin calcium antagonist, in subarachnoid hemorrhage and in ischemic stroke." | 4.79 | From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. ( Di Mascio, R; Marchioli, R; Tognoni, G, 1994) |
| "Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage." | 3.81 | Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. ( Ahtola-Sätilä, T; Forsback, AP; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Simola, O; Tarkia, M, 2015) |
| " In this study, taking advantage of the transparency of larval zebrafish, Danio rerio, we assessed cardiovascular toxicity of seven known human cardiotoxic drugs (aspirin, clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride) and two non-cardiovascular toxicity drugs (gentamicin sulphate and tetracycline hydrochloride) in zebrafish using six specific phenotypic endpoints: heart rate, heart rhythm, pericardial edema, circulation, hemorrhage and thrombosis." | 3.80 | Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. ( Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ, 2014) |
| "We sought to explore whether topical administration of nimodipine improves the abnormal cerebral perfusion following subarachnoid hemorrhage (SAH) in pigs." | 3.79 | Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs. ( Jia, F; Jiang, JY; Wang, F; Yin, YH, 2013) |
| "Nimodipine improved outcome in patients with subarachnoid hemorrhage (SAH) although hypotension limited the dose that could be administered systemically." | 3.78 | Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. ( Ai, J; Cook, DJ; Kan, S; Kasuya, H; Macdonald, RL, 2012) |
| "the aim of this study was to assess and to compare the ability of intrathecal flunarizine and nimodipine to prevent vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 3.77 | Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. ( Civelek, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Secer, HI; Solmaz, I; Temiz, C, 2011) |
| "the aim of this study was to assess and to compare the ability of intrathecal nicergoline and nimodipine in prevention of cerebral vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 3.77 | The effects of intrathecal nicergoline and nimodipine in cerebral vasospasm: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Kircelli, A; Onal, MB; Ongoru, O; Solmaz, I; Ugurel, S, 2011) |
| "To explore the dose-response effects of topical administration of nimodipine on cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rabbits." | 3.75 | Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Jiang, JY; Luo, QZ; Pan, YH; Wang, F; Wang, Y; Yin, YH, 2009) |
| " The aim of the present work was to assess the involvement of P-glycoprotein in carbamazepine and phenobarbital hippocampal pharmacokinetics in an experimental model of epilepsy, induced by repetitive MP administration." | 3.75 | Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ( Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 3.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "The present work was undertaken to examine the central pharmacokinetics of phenytoin (PHT) in an experimental model of epilepsy, induced by administration of 3-mercaptopropionic acid (MP), and possible participation of P-glycoprotein in this model of epilepsy." | 3.74 | Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ( Auzmendi, J; Bramuglia, GF; Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Opezzo, JA; Taira, CA, 2007) |
| "The efficacy of nimodipine was examined in a murine model of subarachnoid hemorrhage (SAH)." | 3.73 | Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. ( Borel, CO; Laskowitz, DT; Lombard, FW; Mesis, RG; Vitek, MP; Wang, H; Warner, DS; Yates, R, 2006) |
| "This study was conducted to investigate the neuroprotective effects of 20(S)-ginsenoside Rg3 on focal cerebral ischemia in rats." | 3.73 | Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. ( Fu, F; Geng, M; Jiang, W; Jiang, Y; Liu, K; Tian, J; Wang, C; Yang, J, 2005) |
| "To compare the individual effects of baicalin and jasminoidin with the combined effect of them on cerebral ischemia-reperfusion injury, and test whether the combined administration of baicalin and jasminoidin can improve the therapeutic effect." | 3.73 | A comparative study on the individual and combined effects of baicalin and jasminoidin on focal cerebral ischemia-reperfusion injury. ( Li, P; Li, PT; Sun, ZH; Wang, YY; Wang, Z; Zhang, WS; Zhang, XJ; Zhang, ZJ, 2006) |
| "The present study evaluates the possible role of dihydropyridine calcium channel antagonist nimodipine on diclofenac analgesia in formalin-induced facial pain model in rats." | 3.72 | Potentiation of antihyperalgesic activity of diclofenac by nimodipine in a formalin model of facial pain in rats. ( Hota, D; Pandhi, P, 2004) |
| "The effect of nimodipine alone and in combination with diazepam or phenytoin was tested in the electroshock-induced mouse model of status epilepticus." | 3.70 | Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus. ( Khosla, P; Pandhi, P, 2000) |
| "It was investigated whether treatment with the calcium channels blocker Nimodipine, a 1,4-dihydropyridine derivative, influences vasculopathy and neuronal injury in experimental pneumococcal meningitis." | 3.69 | Effects of nimodipine on the cerebrovascular and neuronal changes during pneumococcal meningitis in the rat. ( Ayaz, C; Ceviz, A; Geyik, MF; Hoşoglu, S; Inalöz, S; Kemaloglu, MS; Kökoglu, OF; Sari, I, 1997) |
| "Quinine ingestion reportedly induces tinnitus in humans." | 3.68 | Quinine-induced tinnitus in rats. ( Brennan, JF; Jastreboff, PJ; Sasaki, CT, 1991) |
| "The effects of nimodipine and thyrotropin-releasing hormone (TRH) were compared in a clip-compression model of experimental spinal cord injuries (SCI) in rats." | 3.68 | Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine. ( Aktürk, F; Baykal, S; Ceylan, S; Ilbay, K; Kalelioğlu, M; Komsuoğlu, SS; Ozmenoğlu, M; Ozoran, A; Sener, U, 1992) |
| "A novel transient middle cerebral artery (MCA) occlusion model in the rat was used to evaluate the effect of nimodipine on brain edema and mortality." | 3.68 | Effect of nimodipine on ischemia-induced brain edema and mortality in a novel transient middle cerebral artery occlusion model. ( Hara, H; Kogure, K; Nagasawa, H; Onodera, H, 1990) |
| "The efficacy of the calcium channel blocker nimodipine in the prevention of chronic cerebral vasospasm (VSP) and delayed ischemia after subarachnoid hemorrhage (SAH) in monkeys was examined in a blind, randomized, placebo-controlled trial." | 3.67 | Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. ( Boisvert, D; Cook, D; Krueger, C; Norris, S; Nosko, M; Overton, T; Weir, B, 1985) |
| "Male Sprague-Dawley rats under permanent middle cerebral artery occlusion (pMCAO) model, randomly assigned as: model, sham, nimodipine (0." | 3.11 | The therapeutic role of Jingchuan tablet on ischaemic cerebral stroke via the HIF-1α/EPO/VEGFA signalling pathway. ( Fu, Y; Li, D; Liu, Q; Wang, H; Wang, W; Zhang, T; Zhang, Y, 2022) |
| "Nimodipine treatment was found to lower CaV1." | 2.80 | L-type calcium channel blocker ameliorates diabetic encephalopathy by modulating dysregulated calcium homeostasis. ( Sandhir, R; Singhal, K, 2015) |
| "An animal experimental model of vertebrobasilar insufficiency was developed." | 2.66 | Treatment of vertebrobasilar insufficiency. Use of calcium antagonists. ( Hirschberg, M; Hofferberth, B, 1988) |
| "Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago." | 2.44 | Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. ( Amenta, F; Lanari, A; Silvestrelli, G; Tomassoni, D; Traini, E, 2008) |
| "Nimodipine treatment given before experimental ischemic insult, resulting from either vascular occlusion or intracranial hemorrhage or after subarachnoid hemorrhage, maintained or improved blood flow and minimized the severity of subsequent brain damage." | 2.38 | Efficacy of nimodipine in cerebral ischemia or hemorrhage. ( Graham, DI; Harper, AM; McCulloch, J; Mendelow, AD; Teasdale, G, 1990) |
| "Nimodipine was well tolerated and crossed the blood brain barrier, as expected, but there was no effect on Aβ accumulation or on the relative amount of neuritic dystrophy, as assessed by either immunoblot, dot blot or immunofluorescence imaging of Aβ42 and dystrophic neurite marker LAMP1." | 1.72 | Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis. ( Khatri, A; Popovic, J; Sadleir, KR; Vassar, R, 2022) |
| " CG combined with NM is better than NM alone." | 1.62 | Cerebralcare Granule® combined with nimodipine improves cognitive impairment in bilateral carotid artery occlusion rats by reducing lipocalin-2. ( Gao, WY; Han, XY; Ji, HX; Jing, SS; Li, X; Liu, CX; Man, SL; Qiao, O; Wang, J; Wang, WZ; Zhang, XY; Zhang, Y, 2021) |
| "The animal model of cerebral infarction induced by Middle Cerebral Artery Occlusion (MCAO) was blocked by the suture method." | 1.56 | Protective Effect of Paeoniflorin on Acute Cerebral Infarction in Rats. ( Bao, X; Chen, Z; Feng, X; Ma, X; Qiu, C; Tao, X; Wu, W; Yang, J; Zhu, Q, 2020) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 1.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| "Moreover, MN-08 also alleviated cerebral vasospasm in a cisterna magna single-injection model in rabbits." | 1.51 | The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. ( Guo, B; Han, Y; Ju, J; Li, N; Li, S; Liu, Z; Luo, F; Mak, S; Sun, Y; Wang, Y; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhou, Q; Zhu, Z, 2019) |
| "japonica has a protective effect on cerebral ischemia-reperfusion injury in rats." | 1.51 | Protective effect of extract of the Camellia japonica L. on cerebral ischemia-reperfusion injury in rats. ( Lu, W; Wen, J; Xv, L, 2019) |
| "Pretreatment with nimodipine can lower the apoptosis rate of hippocampal neuron to reduce the incidence of postoperative cognitive dysfunction (POCD)." | 1.48 | Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats. ( Bao, Y; Gao, F; Guo, Y; Huo, S; Li, Y; Wang, Q; Wang, X; Xin, X; Yin, C; Zhang, Q, 2018) |
| "Nimodipine is an L-type calcium channel antagonist that reduces excessive calcium influx during pathological conditions (contributing to its neuroprotective properties)." | 1.46 | Autophagy and Akt/CREB signalling play an important role in the neuroprotective effect of nimodipine in a rat model of vascular dementia. ( Hu, M; Liu, Z; Lv, P; Qi, Q; Wang, H; Xu, J; Zhu, Y, 2017) |
| "Nimodipine treatment attenuated clinical EAE and spinal cord degeneration and promoted remyelination." | 1.46 | Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis. ( Ergün, S; Hell, JW; Jörg, S; Koeniger, T; Kuerten, S; Linker, RA; Schampel, A; Scholz, CJ; Volovitch, O; Wischmeyer, E; Wunsch, M, 2017) |
| "Female mice received whole brain irradiation (WBI) and were treated with saline, nimodipine, hUC-MSCs, or hUC-MSCs combined with nimodipine." | 1.43 | Neuroprotective effects of human umbilical cord-derived mesenchymal stromal cells combined with nimodipine against radiation-induced brain injury through inhibition of apoptosis. ( Duan, HF; Li, T; Liu, J; Liu, Y; Lu, Y; Qin, YR; Wang, GH; Wu, XB, 2016) |
| "Nimodipine and aspirin were set as positive control separately." | 1.43 | Sodium Sulfide, a Hydrogen Sulfide-Releasing Molecule, Attenuates Acute Cerebral Ischemia in Rats. ( Chen, B; Cheng, MH; Fan, BS; Shi, HQ; Tian, JS; Yu, JG; Zhang, Y, 2016) |
| "LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by treatment with nimodipine." | 1.42 | Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. ( Adzovic, L; Crockett, AM; D'Angelo, HM; Hopp, SC; Kaercher, RM; Royer, SE; Wenk, GL, 2015) |
| "Ischemia-reperfusion injury was induced by the four-vessel occlusion method and continued for 30 days." | 1.39 | The molecular and electrophysiological mechanism of buyanghuanwu decoction in learning and memory ability of vascular dementia rats. ( Hongbo, Z; Jinglong, T; Jun, L; Shasha, L; Tao, Q; Weijuan, G, 2013) |
| "Febrile seizures are associated with increased brain temperature and are often resistant to treatments with antiepileptic drugs, such as carbamazepine and phenytoin, which are sodium channel blockers." | 1.39 | Temperature-sensitive Cav1.2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures. ( Cho, K; Koh, S; Martina, M; Mlsna, L; Pollema-Mays, SL; Radzicki, D; Yau, HJ, 2013) |
| "Human cerebral malaria (HCM) is a life-threatening complication caused by Plasmodium falciparum infection that continues to be a major global health problem despite optimal anti-malarial treatment." | 1.39 | Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria. ( Carvalho, LJ; Clemmer, L; Frangos, JA; Martins, YC; Ong, PK; Orjuela-Sánchez, P; Zanini, GM, 2013) |
| "Nimodipine was administered orally in diets (0, 20, or 200 ppm, producing approximately 0, 2, or 20 mg/kg/day of nimodipine)." | 1.39 | Dietary nimodipine delays the onset of methylmercury neurotoxicity in mice. ( Bailey, JM; Hutsell, BA; Newland, MC, 2013) |
| "Nimodipine is an effect-proven agent in CVS, but dotarizine may take place of it." | 1.37 | Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Solmaz, I; Tehli, O, 2011) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 1.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "Nimodipine treatment in cerebral vasospasm is useful." | 1.37 | Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Civelek, E; Isikay, I; Kircelli, A; Narin, F; Onal, MB; Solmaz, I; Ugurel, S; Yakupoglu, H, 2011) |
| "Dopamine deficiency associated with Parkinson's disease (PD) results in numerous changes in striatal transmitter function and neuron morphology." | 1.36 | Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. ( Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K, 2010) |
| "Rabbits symptomatic cerebral vasospasm model was built though Endo method, among the 40 rabbits, 8 died or had severe nervous system syndrome, the other 32 were randomly divided into 4 groups:group A, control group, injection of normal saline to the cisterna magna;group B, subarachnoid hemorrhage;group C, injection of human urinary tissue kallikreins;group D, treated with Nimodipine." | 1.35 | [Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm]. ( Chen, WJ; Hu, ZY; Meng, YN; Mo, YC; Pei, SL; Wang, JL; Zhou, LP, 2009) |
| "Traumatic subarachnoid hemorrhage is a common finding following traumatic brain injury." | 1.35 | Experimental subarachnoid hemorrhage in the rat: influences of nimodipine. ( Brinker, T; Herrmann, B; Samii, M; Thomas, S, 2008) |
| "Nimodipine was further studied using a higher and escalating doses of morphine (20-30 mg/kg twice daily for 14 days)." | 1.35 | Nimodipine is more effective than nifedipine in attenuating morphine tolerance on chronic co-administration in the rat tail-flick test. ( Gupta, A; Mishra, P; Ray, SB; Verma, D; Wadhwa, S, 2008) |
| "Both nimodipine treatments prevented the memory deficits when these were measured between 1 and 2 months after alcohol withdrawal." | 1.35 | Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase. ( Brooks, SP; Croft, AP; Little, HJ; Norman, G; Shaw, SG, 2008) |
| "Isradipine-treated animals displayed a dose-dependent reduction in L-DOPA-induced rotational behavior and abnormal involuntary movements." | 1.35 | Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. ( Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ, 2009) |
| "Nimodipine was given twice daily by subcutaneous injections." | 1.34 | Calcium antagonism in neonatal rats with kaolin-induced hydrocephalus. ( Del Bigio, MR; Khan, OH; McPhee, LC; Moddemann, LN, 2007) |
| "One of the main limitations of intracerebral hemorrhage (ICH) research is lack of reproducible animal models." | 1.33 | Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. ( Ma, B; Zhang, J, 2006) |
| " The animals were treated with either one of the drugs at previously defined relevant dosage or control." | 1.33 | Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine. ( Gahm, C; Holmin, S; Mathiesen, T; Rudehill, S, 2005) |
| "Nimodipine has a protective action on brain injury by blocking a series of pathological reactions induced by neuronal calcium overload, and by reducing the spasm of brain vessels and improving cerebral blood flow." | 1.32 | Therapeutic effect of nimodipine on experimental brain injury. ( Wang, ZG; Yang, SY, 2003) |
| "Nimodipine-treated animals were then matched with vehicle-treated controls for both study conditions." | 1.32 | Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia. ( Burnett, MG; Gomi, S; Greenberg, JH; Karp, A, 2004) |
| "Bupivacaine is a local anesthetic frequently used in clinical practice, and cardiotoxicity is one of its severe side effects." | 1.30 | The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study. ( Adsan, H; Onaran, O; Tulunay, M, 1998) |
| "Treatment with nimodipine (20 mg kg-1) from week 6 onwards significantly increased the sciatic nerve blood flow as compared to placebo-treated diabetic BB/Wor rats." | 1.29 | Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat. ( Biessels, G; Bravenboer, B; de Wildt, DJ; Gispen, WH; Kappelle, AC; Traber, J; van Buren, T, 1994) |
| "Therefore, in two rat models of focal cerebral ischemia we studied the effects of gamma 2-MSH, with nimodipine, a Ca2+ channel antagonist, as a reference compound, on parasagittal laser-Doppler-assessed cortical blood flow and infarction volume." | 1.29 | The effects of gamma 2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion. ( De Wildt, DJ; Herz, RC; Versteeg, DH, 1996) |
| "Reperfusion injury is a pathophysiological entity distinct from the primary ischaemic injury; the oxygen arriving with blood recirculation, although necessary for alleviating the ischaemic status, may be harmful and provoke additional injury in the already damaged tissue." | 1.29 | Can nimodipine prevent ischaemic reperfusion injury in the rat brain? ( Albariño, AR; Carceller, F; Díez-Tejedor, E; Gutiérrez-Molina, M; López-Pajares, R; Roda, JM, 1993) |
| " dosing for 7 days (P< 0." | 1.29 | Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. ( Brown, CM; Calder, C; Kenny, BA; Linton, C; Patmore, L; Small, C; Spedding, M, 1995) |
| "Brain damage after resuscitation from cardiac arrest is believed to be related to calcium influx in ischaemic neurons and to postischaemic calcium-dependent vasospasm." | 1.28 | Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat. ( Bogaert, MG; Buylaert, WA; Calle, PA; De Ridder, L, 1990) |
| "The nimodipine-treated animals had less clinical evidence of infarction compared to controls." | 1.28 | The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model. ( Fifield, MS; Hadley, MN; Johnson, PC; Rigamonti, D; Spetzler, RF; Zabramski, JM, 1989) |
| " Half the animals were pretreated with an intravenous infusion of the calcium antagonistic nimodipine, in a dosage comparable with clinical levels." | 1.28 | An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage. ( Bentivoglio, P; Branston, NM; Dorsch, NW; Harris, RJ; Symon, L, 1989) |
| "Nimodipine (Nimotop) was administered to spontaneously hypertensive rats (SHR) in order to investigate its ameliorative effect on central nervous disorders associated with hypertension." | 1.27 | Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats. ( Nomura, M, 1988) |
| "Nimodipine was administered by intravenous infusion to six male baboons before, during, and after 6 hours of middle cerebral artery occlusion." | 1.27 | The effect of nimodipine on intracranial pressure. Volume-pressure studies in a primate model. ( Bichard, WD; Fifield, MS; Hadley, MN; Hodak, JA; Spetzler, RF, 1987) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (9.49) | 18.7374 |
| 1990's | 27 (19.71) | 18.2507 |
| 2000's | 40 (29.20) | 29.6817 |
| 2010's | 48 (35.04) | 24.3611 |
| 2020's | 9 (6.57) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhang, XY | 1 |
| Jing, SS | 1 |
| Qiao, O | 1 |
| Han, XY | 1 |
| Wang, WZ | 1 |
| Ji, HX | 1 |
| Zhang, Y | 6 |
| Li, X | 1 |
| Wang, J | 3 |
| Man, SL | 1 |
| Liu, CX | 1 |
| Gao, WY | 1 |
| Sadleir, KR | 1 |
| Popovic, J | 1 |
| Khatri, A | 1 |
| Vassar, R | 1 |
| Liu, Q | 1 |
| Zhang, T | 2 |
| Wang, H | 5 |
| Fu, Y | 1 |
| Wang, W | 1 |
| Li, D | 1 |
| Denaroso, GE | 1 |
| Smith, Z | 1 |
| Angeliu, CG | 1 |
| Cheli, VT | 1 |
| Wang, C | 2 |
| Paez, PM | 1 |
| Wu, W | 1 |
| Qiu, C | 1 |
| Feng, X | 1 |
| Tao, X | 1 |
| Zhu, Q | 1 |
| Chen, Z | 1 |
| Ma, X | 2 |
| Yang, J | 3 |
| Bao, X | 1 |
| Li, JW | 1 |
| Ren, SH | 1 |
| Ren, JR | 1 |
| Zhen, ZG | 1 |
| Li, LR | 1 |
| Hao, XD | 1 |
| Ji, HM | 1 |
| Zhang, W | 1 |
| Wen, J | 2 |
| Jiang, Y | 2 |
| Hu, Q | 1 |
| Wei, S | 1 |
| Li, H | 3 |
| Odorico, SK | 1 |
| Shulzhenko, NO | 1 |
| Zeng, W | 1 |
| Dingle, AM | 1 |
| Francis, DO | 1 |
| Poore, SO | 1 |
| Schampel, A | 1 |
| Volovitch, O | 1 |
| Koeniger, T | 1 |
| Scholz, CJ | 1 |
| Jörg, S | 1 |
| Linker, RA | 1 |
| Wischmeyer, E | 1 |
| Wunsch, M | 1 |
| Hell, JW | 1 |
| Ergün, S | 1 |
| Kuerten, S | 1 |
| Hu, M | 2 |
| Liu, Z | 3 |
| Lv, P | 2 |
| Zhu, Y | 2 |
| Qi, Q | 2 |
| Xu, J | 2 |
| Gao, L | 1 |
| Wei, C | 2 |
| Ke, J | 1 |
| Li, J | 2 |
| Xu, L | 1 |
| Liu, H | 1 |
| Li, S | 2 |
| Yang, M | 1 |
| Chen, Y | 2 |
| Guo, Z | 1 |
| Peng, X | 1 |
| Xie, W | 1 |
| Chen, L | 1 |
| Tan, Z | 1 |
| Zhang, Q | 1 |
| Li, Y | 1 |
| Bao, Y | 1 |
| Yin, C | 1 |
| Xin, X | 1 |
| Guo, Y | 1 |
| Gao, F | 2 |
| Huo, S | 1 |
| Wang, X | 1 |
| Wang, Q | 1 |
| Di Curzio, DL | 1 |
| Mao, X | 1 |
| Baker, A | 1 |
| Del Bigio, MR | 2 |
| Lu, W | 1 |
| Xv, L | 1 |
| Yan, B | 1 |
| Sun, Y | 2 |
| Zeng, J | 1 |
| Li, C | 1 |
| Song, P | 1 |
| Zhang, L | 1 |
| Yang, X | 2 |
| Wu, Y | 1 |
| Ma, P | 1 |
| Qin, Y | 1 |
| Li, G | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Gu, J | 1 |
| Christensen, ST | 1 |
| Johansson, SE | 1 |
| Radziwon-Balicka, A | 1 |
| Warfvinge, K | 1 |
| Haanes, KA | 1 |
| Edvinsson, L | 1 |
| Luo, F | 1 |
| Wu, L | 1 |
| Zhang, Z | 2 |
| Zhu, Z | 2 |
| Guo, B | 1 |
| Li, N | 1 |
| Ju, J | 1 |
| Zhou, Q | 1 |
| Mak, S | 1 |
| Han, Y | 1 |
| Wang, Y | 3 |
| Zhang, G | 2 |
| Zhang, J | 2 |
| Cao, H | 1 |
| Ma, J | 1 |
| Gao, Y | 1 |
| Zhang, X | 2 |
| Zhang, F | 1 |
| Chu, L | 1 |
| Chang, LP | 1 |
| Jia, ZH | 1 |
| Bailey, JM | 1 |
| Hutsell, BA | 1 |
| Newland, MC | 2 |
| Martins, YC | 1 |
| Clemmer, L | 1 |
| Orjuela-Sánchez, P | 1 |
| Zanini, GM | 1 |
| Ong, PK | 1 |
| Frangos, JA | 1 |
| Carvalho, LJ | 1 |
| Radzicki, D | 1 |
| Yau, HJ | 1 |
| Pollema-Mays, SL | 1 |
| Mlsna, L | 1 |
| Cho, K | 1 |
| Koh, S | 1 |
| Martina, M | 1 |
| Jinglong, T | 1 |
| Weijuan, G | 1 |
| Jun, L | 1 |
| Tao, Q | 1 |
| Hongbo, Z | 1 |
| Shasha, L | 1 |
| James, ML | 1 |
| Venkatraman, TN | 1 |
| Wilson, LJ | 1 |
| Lyuboslavsky, P | 1 |
| Myers, SJ | 1 |
| Lascola, CD | 1 |
| Laskowitz, DT | 2 |
| Ju, L | 1 |
| Zheng, J | 1 |
| Singhal, K | 1 |
| Sandhir, R | 1 |
| Koskimäki, J | 1 |
| Tarkia, M | 1 |
| Ahtola-Sätilä, T | 1 |
| Saloranta, L | 1 |
| Simola, O | 1 |
| Forsback, AP | 1 |
| Laakso, A | 1 |
| Frantzén, J | 1 |
| Young, AM | 1 |
| Karri, SK | 1 |
| Helmy, A | 1 |
| Budohoski, KP | 1 |
| Kirollos, RW | 1 |
| Bulters, DO | 1 |
| Kirkpatrick, PJ | 1 |
| Ogilvy, CS | 1 |
| Trivedi, RA | 1 |
| Hopp, SC | 1 |
| D'Angelo, HM | 1 |
| Royer, SE | 1 |
| Kaercher, RM | 1 |
| Crockett, AM | 1 |
| Adzovic, L | 1 |
| Wenk, GL | 1 |
| Wang, GH | 1 |
| Liu, Y | 1 |
| Wu, XB | 1 |
| Lu, Y | 1 |
| Liu, J | 1 |
| Qin, YR | 1 |
| Li, T | 1 |
| Duan, HF | 1 |
| Shi, HQ | 1 |
| Cheng, MH | 1 |
| Fan, BS | 1 |
| Tian, JS | 1 |
| Yu, JG | 1 |
| Chen, B | 1 |
| Shen, AN | 1 |
| Cummings, C | 1 |
| Hoffman, D | 1 |
| Pope, D | 1 |
| Arnold, M | 1 |
| Ray, SB | 2 |
| Mishra, P | 1 |
| Verma, D | 2 |
| Gupta, A | 1 |
| Wadhwa, S | 2 |
| Brooks, SP | 1 |
| Croft, AP | 1 |
| Norman, G | 1 |
| Shaw, SG | 1 |
| Little, HJ | 2 |
| Schuster, S | 1 |
| Doudnikoff, E | 1 |
| Rylander, D | 1 |
| Berthet, A | 1 |
| Aubert, I | 1 |
| Ittrich, C | 1 |
| Bloch, B | 1 |
| Cenci, MA | 1 |
| Surmeier, DJ | 1 |
| Hengerer, B | 1 |
| Bezard, E | 1 |
| Tomassoni, D | 1 |
| Lanari, A | 1 |
| Silvestrelli, G | 1 |
| Traini, E | 1 |
| Amenta, F | 1 |
| Yin, YH | 2 |
| Wang, F | 2 |
| Pan, YH | 1 |
| Luo, QZ | 1 |
| Jiang, JY | 2 |
| Thomas, S | 1 |
| Herrmann, B | 1 |
| Samii, M | 1 |
| Brinker, T | 1 |
| Höcht, C | 2 |
| Lazarowski, A | 2 |
| Gonzalez, NN | 2 |
| Mayer, MA | 1 |
| Opezzo, JA | 2 |
| Taira, CA | 2 |
| Girardi, E | 2 |
| Jia, F | 1 |
| Pei, SL | 1 |
| Meng, YN | 1 |
| Wang, JL | 2 |
| Hu, ZY | 1 |
| Mo, YC | 2 |
| Zhou, LP | 1 |
| Chen, WJ | 1 |
| Bilginer, B | 3 |
| Onal, MB | 6 |
| Narin, F | 3 |
| Soylemezoglu, F | 2 |
| Ziyal, IM | 1 |
| Ozgen, T | 2 |
| Emerick, GL | 1 |
| Peccinini, RG | 1 |
| de Oliveira, GH | 1 |
| Bekker, A | 1 |
| Haile, M | 1 |
| Li, YS | 1 |
| Galoyan, S | 1 |
| Garcia, E | 1 |
| Quartermain, D | 2 |
| Kamer, A | 1 |
| Blanck, T | 1 |
| Soderstrom, KE | 1 |
| O'Malley, JA | 1 |
| Levine, ND | 1 |
| Sortwell, CE | 1 |
| Collier, TJ | 1 |
| Steece-Collier, K | 1 |
| Bie, XD | 1 |
| Han, J | 1 |
| Dai, HB | 1 |
| Civelek, E | 4 |
| Kircelli, A | 4 |
| Solmaz, I | 4 |
| Ugurel, S | 2 |
| Isikay, I | 1 |
| Yakupoglu, H | 1 |
| Ziyal, MI | 1 |
| Tehli, O | 1 |
| Izci, Y | 2 |
| Erdogan, E | 2 |
| Gonul, E | 3 |
| Temiz, C | 1 |
| Secer, HI | 1 |
| Ongoru, O | 1 |
| Sun, BL | 1 |
| Xia, ZL | 1 |
| Yang, MF | 1 |
| Yu, JM | 1 |
| Liang, DD | 1 |
| Tao, F | 1 |
| Geng, WJ | 1 |
| Lu, J | 1 |
| Wan, H | 1 |
| Nishimoto, K | 2 |
| Kumai, Y | 2 |
| Minoda, R | 2 |
| Yumoto, E | 2 |
| Cook, DJ | 1 |
| Kan, S | 1 |
| Ai, J | 1 |
| Kasuya, H | 1 |
| Macdonald, RL | 1 |
| Zhao, WJ | 1 |
| Wu, C | 1 |
| Sanuki, T | 1 |
| Tator, CH | 2 |
| Hashimoto, R | 1 |
| Raich, A | 1 |
| Norvell, D | 1 |
| Fehlings, MG | 1 |
| Harrop, JS | 1 |
| Guest, J | 1 |
| Aarabi, B | 1 |
| Grossman, RG | 1 |
| Ismailoglu, O | 1 |
| Atilla, P | 1 |
| Palaoglu, S | 2 |
| Cakar, N | 1 |
| Yasar, U | 1 |
| Kilinc, K | 2 |
| Kaptanoglu, E | 1 |
| Zhu, JJ | 1 |
| Xu, YQ | 1 |
| He, JH | 1 |
| Yu, HP | 1 |
| Huang, CJ | 1 |
| Gao, JM | 1 |
| Dong, QX | 1 |
| Xuan, YX | 1 |
| Li, CQ | 1 |
| da Cruz, GM | 1 |
| Felipe, CF | 1 |
| Scorza, FA | 1 |
| da Costa, MA | 1 |
| Tavares, AF | 1 |
| Menezes, ML | 1 |
| de Andrade, GM | 1 |
| Leal, LK | 1 |
| Brito, GA | 1 |
| da Graça Naffah-Mazzacoratti, M | 1 |
| Cavalheiro, EA | 1 |
| de Barros Viana, GS | 1 |
| Bell, KF | 1 |
| Bent, RJ | 1 |
| Meese-Tamuri, S | 1 |
| Ali, A | 1 |
| Forder, JP | 1 |
| Aarts, MM | 1 |
| Ochi, K | 2 |
| Kinoshita, H | 2 |
| Kenmochi, M | 2 |
| Nishino, H | 2 |
| Ohashi, T | 2 |
| Sekiya, T | 1 |
| Yagihashi, A | 1 |
| Asano, K | 1 |
| Suzuki, S | 1 |
| Turgut, M | 1 |
| Uysal, A | 1 |
| Uslu, S | 1 |
| Tavus, N | 1 |
| Yurtseven, ME | 1 |
| Kriz, J | 1 |
| Gowing, G | 1 |
| Julien, JP | 1 |
| Zausinger, S | 1 |
| Westermaier, T | 1 |
| Plesnila, N | 1 |
| Steiger, HJ | 1 |
| Schmid-Elsaesser, R | 1 |
| Yang, SY | 1 |
| Wang, ZG | 1 |
| Gomi, S | 1 |
| Burnett, MG | 1 |
| Karp, A | 1 |
| Greenberg, JH | 1 |
| Mastropaolo, J | 1 |
| Rosse, RB | 1 |
| Deutsch, SI | 1 |
| Hota, D | 2 |
| Pandhi, P | 2 |
| Tian, J | 1 |
| Fu, F | 1 |
| Geng, M | 1 |
| Jiang, W | 1 |
| Liu, K | 1 |
| Gahm, C | 1 |
| Holmin, S | 1 |
| Rudehill, S | 1 |
| Mathiesen, T | 1 |
| Squadrito, F | 1 |
| Sturniolo, R | 1 |
| Altavilla, D | 1 |
| Caputi, AP | 1 |
| Ma, B | 1 |
| Li, LL | 1 |
| Wang, L | 1 |
| Feng, N | 1 |
| Wang, XL | 1 |
| Mesis, RG | 1 |
| Lombard, FW | 1 |
| Yates, R | 1 |
| Vitek, MP | 1 |
| Borel, CO | 1 |
| Warner, DS | 1 |
| Zhang, ZJ | 1 |
| Li, P | 1 |
| Wang, Z | 1 |
| Li, PT | 1 |
| Zhang, WS | 1 |
| Sun, ZH | 1 |
| Zhang, XJ | 1 |
| Wang, YY | 1 |
| Auzmendi, J | 1 |
| Bramuglia, GF | 1 |
| Gupta, H | 1 |
| Ahuja, RK | 1 |
| Srivastava, DN | 1 |
| Bean, BP | 1 |
| Khan, OH | 1 |
| McPhee, LC | 1 |
| Moddemann, LN | 1 |
| Bansal, V | 1 |
| Pattanaik, S | 1 |
| Liu, A | 1 |
| Zhou, Y | 1 |
| San, X | 1 |
| Jin, T | 1 |
| Jin, Y | 1 |
| Fröba, G | 1 |
| Bracht, H | 1 |
| Hauser, B | 1 |
| Chkhouta, AB | 1 |
| Huber-Lang, M | 1 |
| Rittirsch, D | 1 |
| Brückner, UB | 1 |
| Radermacher, P | 1 |
| Schelzig, H | 1 |
| Roda, JM | 2 |
| Carceller, F | 2 |
| Díez-Tejedor, E | 2 |
| Avendaño, C | 1 |
| Pointillard, V | 1 |
| Petitjean, ME | 1 |
| Winkler, T | 1 |
| Gutiérrez-Molina, M | 1 |
| López-Pajares, R | 1 |
| Albariño, AR | 1 |
| Kappelle, AC | 1 |
| Biessels, G | 1 |
| Bravenboer, B | 1 |
| van Buren, T | 1 |
| Traber, J | 1 |
| de Wildt, DJ | 2 |
| Gispen, WH | 1 |
| Schindler, I | 1 |
| Steltzer, H | 1 |
| Weindlmayr-Goettel, M | 1 |
| Steinbereithner, K | 1 |
| Brown, CM | 1 |
| Calder, C | 1 |
| Linton, C | 1 |
| Small, C | 1 |
| Kenny, BA | 1 |
| Spedding, M | 1 |
| Patmore, L | 1 |
| Herz, RC | 1 |
| Versteeg, DH | 1 |
| Ison, JR | 1 |
| Payman, GH | 1 |
| Palmer, MJ | 1 |
| Walton, JP | 1 |
| Jonas, S | 2 |
| Tran, AQ | 1 |
| Eisenberg, E | 1 |
| Azam, M | 1 |
| Viera, D | 1 |
| Grumet, S | 1 |
| Hoşoglu, S | 1 |
| Ceviz, A | 1 |
| Kemaloglu, MS | 1 |
| Sari, I | 1 |
| Inalöz, S | 1 |
| Geyik, MF | 1 |
| Kökoglu, OF | 1 |
| Ayaz, C | 1 |
| Meneses, A | 1 |
| Hong, E | 1 |
| Adsan, H | 1 |
| Tulunay, M | 1 |
| Onaran, O | 1 |
| Imamura, H | 1 |
| Mirzoian, RS | 1 |
| Topchian, AV | 1 |
| Kanaian, AS | 1 |
| Balasanian, MG | 1 |
| Di Mascio, R | 1 |
| Marchioli, R | 1 |
| Tognoni, G | 1 |
| Lanier, WL | 1 |
| Fureman, BE | 1 |
| Campbell, DB | 1 |
| Hess, EJ | 1 |
| Khosla, P | 1 |
| Holt, JD | 1 |
| Watson, WP | 1 |
| Ercan, M | 1 |
| Inci, S | 1 |
| Aypar, U | 1 |
| Horn, J | 1 |
| de Haan, RJ | 1 |
| Vermeulen, M | 1 |
| Luiten, PG | 1 |
| Limburg, M | 1 |
| Grehn, F | 1 |
| Hogan, MJ | 1 |
| Hakim, AM | 1 |
| Tadie, M | 1 |
| Rickels, E | 1 |
| Zumkeller, M | 1 |
| Ceylan, S | 2 |
| Ilbay, K | 1 |
| Baykal, S | 1 |
| Sener, U | 1 |
| Ozmenoğlu, M | 1 |
| Kalelioğlu, M | 1 |
| Aktürk, F | 1 |
| Komsuoğlu, SS | 1 |
| Ozoran, A | 1 |
| Jastreboff, PJ | 1 |
| Brennan, JF | 1 |
| Sasaki, CT | 1 |
| Handa, J | 1 |
| Shiino, A | 1 |
| Kidooka, M | 1 |
| Teasdale, G | 1 |
| Mendelow, AD | 1 |
| Graham, DI | 1 |
| Harper, AM | 1 |
| McCulloch, J | 1 |
| Hara, H | 1 |
| Onodera, H | 1 |
| Nagasawa, H | 1 |
| Kogure, K | 1 |
| Calle, PA | 1 |
| Bogaert, MG | 1 |
| De Ridder, L | 1 |
| Buylaert, WA | 1 |
| Pellegrini-Giampietro, DE | 1 |
| Bacciottini, L | 1 |
| Carlà, V | 1 |
| Moroni, F | 1 |
| Beal, MF | 1 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Martin, JB | 1 |
| Hadley, MN | 2 |
| Zabramski, JM | 1 |
| Spetzler, RF | 3 |
| Rigamonti, D | 1 |
| Fifield, MS | 2 |
| Johnson, PC | 1 |
| Dorsch, NW | 1 |
| Branston, NM | 1 |
| Harris, RJ | 1 |
| Bentivoglio, P | 1 |
| Symon, L | 1 |
| Wauquier, A | 1 |
| Melis, W | 1 |
| Janssen, PA | 1 |
| Hofferberth, B | 1 |
| Hirschberg, M | 1 |
| Nomura, M | 1 |
| Bichard, WD | 1 |
| Hodak, JA | 1 |
| Sahlin, C | 1 |
| Brismar, J | 1 |
| Delgado, T | 1 |
| Owman, C | 1 |
| Salford, LG | 1 |
| Svendgaard, NA | 1 |
| Gioia, AE | 1 |
| White, RP | 1 |
| Bakhtian, B | 1 |
| Robertson, JT | 1 |
| Zabramski, J | 1 |
| Bonstelle, C | 1 |
| Nosko, M | 1 |
| Weir, B | 1 |
| Krueger, C | 1 |
| Cook, D | 1 |
| Norris, S | 1 |
| Overton, T | 1 |
| Boisvert, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for nimodipine and Disease Models, Animal
| Article | Year |
|---|---|
Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies.
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; D | 2008 |
Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury.
Topics: Animals; Disease Models, Animal; Glyburide; Humans; Magnesium Sulfate; Minocycline; Neuroprotective | 2012 |
Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
Topics: Animals; Cerebral Infarction; Cerebrovascular Disorders; Clinical Trials as Topic; Disease Models, A | 1997 |
From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders.
Topics: Animals; Brain Ischemia; Cause of Death; Cerebrovascular Disorders; Controlled Clinical Trials as To | 1994 |
Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
Topics: Animals; Anticoagulants; Calcium; Calcium Channel Blockers; Cerebral Infarction; Clinical Trials as | 2001 |
Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Clinical Trials as Topic; Disease Models, Animal; | 2001 |
[Ca antagonists in neurosurgical practice].
Topics: Animals; Anticonvulsants; Brain; Calcium Channel Blockers; Cerebral Infarction; Disease Models, Anim | 1990 |
Efficacy of nimodipine in cerebral ischemia or hemorrhage.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Humans; Ischemic Attack, Transient; Nimodipine | 1990 |
4 trials available for nimodipine and Disease Models, Animal
| Article | Year |
|---|---|
The therapeutic role of Jingchuan tablet on ischaemic cerebral stroke via the HIF-1α/EPO/VEGFA signalling pathway.
Topics: Animals; Brain Ischemia; Chlorogenic Acid; Disease Models, Animal; Gallic Acid; Infarction, Middle C | 2022 |
L-type calcium channel blocker ameliorates diabetic encephalopathy by modulating dysregulated calcium homeostasis.
Topics: Animals; Blood Glucose; Brain; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium- | 2015 |
[Effect of nimodipine on vasospasm of cortical arteries. Experimental study].
Topics: Animals; Cerebral Arteries; Cerebral Cortex; Disease Models, Animal; Dogs; Drug Evaluation; Female; | 1992 |
Treatment of vertebrobasilar insufficiency. Use of calcium antagonists.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Double-Blind Method; Flunarizine; Humans; | 1988 |
125 other studies available for nimodipine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Cerebralcare Granule® combined with nimodipine improves cognitive impairment in bilateral carotid artery occlusion rats by reducing lipocalin-2.
Topics: Animals; Carotid Arteries; China; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; | 2021 |
Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis.
Topics: Administration, Oral; Alzheimer Disease; Animals; Calcium Channel Blockers; Disease Models, Animal; | 2022 |
Deletion of voltage-gated calcium channels in astrocytes decreases neuroinflammation and demyelination in a murine model of multiple sclerosis.
Topics: Animals; Astrocytes; Calcium Channels; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experi | 2023 |
Protective Effect of Paeoniflorin on Acute Cerebral Infarction in Rats.
Topics: Acute Disease; Animals; Brain; Cerebral Infarction; Disease Models, Animal; Glucosides; Lipid Peroxi | 2020 |
Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis.
Topics: Animals; Antihypertensive Agents; Cognitive Dysfunction; Disease Models, Animal; Down-Regulation; Ma | 2020 |
l-Borneol ameliorates cerebral ischaemia by downregulating the mitochondrial calcium uniporter-induced apoptosis cascade in pMCAO rats.
Topics: Animals; Apoptosis; Brain Ischemia; Calcium Channels; Camphanes; Disease Models, Animal; Dose-Respon | 2021 |
Effect of Nimodipine and Botulinum Toxin A on Peripheral Nerve Regeneration in Rats: A Pilot Study.
Topics: Animals; Botulinum Toxins, Type A; Combined Modality Therapy; Disease Models, Animal; Humans; Male; | 2021 |
Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis.
Topics: Animals; Apoptosis; Calcium Channels, L-Type; Cells, Cultured; Disease Models, Animal; Encephalomyel | 2017 |
Nimodipine activates neuroprotective signaling events and inactivates autophages in the VCID rat hippocampus.
Topics: Animals; Autophagy; Carotid Artery Diseases; Carotid Artery, Common; Cognitive Dysfunction; Cyclic A | 2017 |
Biomimetic synthesis and evaluation of histidine-derivative templated chiral mesoporous silica for improved oral delivery of the poorly water-soluble drug, nimodipine.
Topics: Administration, Oral; Animals; Biological Availability; Biomimetic Materials; Biomimetics; Calcium C | 2018 |
Nimodipine represses AMPK phosphorylation and excessive autophagy after chronic cerebral hypoperfusion in rats.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain; Calcium Channel Blockers; Calcium Channels | 2018 |
Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats.
Topics: Aging; Animals; Apoptosis; Calcineurin; Calcium Channel Blockers; Cognition Disorders; Disease Model | 2018 |
Nimodipine treatment does not benefit juvenile ferrets with kaolin-induced hydrocephalus.
Topics: Animals; Animals, Newborn; Brain; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Re | 2018 |
Protective effect of extract of the Camellia japonica L. on cerebral ischemia-reperfusion injury in rats.
Topics: Animals; Brain Ischemia; Camellia; Disease Models, Animal; Female; Immunoglobulin G; L-Lactate Dehyd | 2019 |
Combined use of vitamin E and nimodipine ameliorates dibutyl phthalate-induced memory deficit and apoptosis in mice by inhibiting the ERK 1/2 pathway.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Calcium Channel Blockers; Calcium Signaling; Dib | 2019 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats.
Topics: Animals; Butadienes; Calcium Channel Blockers; Cerebral Arteries; Disease Models, Animal; Male; Mito | 2019 |
The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models.
Topics: Animals; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; HEK293 Cells; Hum | 2019 |
Nephroprotective effect of calcium channel blockers against toxicity of lead exposure in mice.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Body Weight; Calcium Channel Blockers; Creatinine; Cytoprot | 2013 |
[Effects of tongxinluo on angiogenesis and the volume of blood perfusion in ischemic stroke rats].
Topics: Animals; Brain Ischemia; Disease Models, Animal; Drugs, Chinese Herbal; Hemoperfusion; Male; Neovasc | 2012 |
Dietary nimodipine delays the onset of methylmercury neurotoxicity in mice.
Topics: Animals; Behavior, Animal; Brain; Calcium Channel Blockers; Diet; Disease Models, Animal; Dose-Respo | 2013 |
Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria.
Topics: Administration, Intravenous; Animals; Antihypertensive Agents; Antimalarials; Artemisinins; Artesuna | 2013 |
Temperature-sensitive Cav1.2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures.
Topics: Action Potentials; Anilides; Animals; Animals, Newborn; Cadmium Chloride; Calcium Channel Blockers; | 2013 |
The molecular and electrophysiological mechanism of buyanghuanwu decoction in learning and memory ability of vascular dementia rats.
Topics: Action Potentials; Animals; Apoptosis; Calcium Channel Blockers; Calcium-Calmodulin-Dependent Protei | 2013 |
pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.
Topics: Animals; Behavior, Animal; Calcium Channel Blockers; Disease Models, Animal; Hydrogen-Ion Concentrat | 2014 |
Research on recovery function of two drugs combination on rat sciatic nerve injury regeneration model.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Male; Nerve Growth Factor; Nerve Regener | 2014 |
Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model.
Topics: Animals; Delayed-Action Preparations; Disease Models, Animal; Dogs; Intracranial Aneurysm; Nimodipin | 2015 |
Pharmacologic Management of Subarachnoid Hemorrhage.
Topics: Adrenal Cortex Hormones; Animals; Anticoagulants; Apoptosis; Brain Ischemia; Calcium Channel Blocker | 2015 |
Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Calcium Chan | 2015 |
Neuroprotective effects of human umbilical cord-derived mesenchymal stromal cells combined with nimodipine against radiation-induced brain injury through inhibition of apoptosis.
Topics: Animals; Apoptosis; Astrocytes; beta-Globins; Body Weight; Brain Injuries; Cell Count; Cell Differen | 2016 |
Sodium Sulfide, a Hydrogen Sulfide-Releasing Molecule, Attenuates Acute Cerebral Ischemia in Rats.
Topics: Acute Disease; Analysis of Variance; Animals; Apoptosis; Aspirin; Blood Pressure; Cell Survival; Cel | 2016 |
Aging, motor function, and sensitivity to calcium channel blockers: An investigation using chronic methylmercury exposure.
Topics: Aging; Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; | 2016 |
Autophagy and Akt/CREB signalling play an important role in the neuroprotective effect of nimodipine in a rat model of vascular dementia.
Topics: Animals; Autophagy; CA1 Region, Hippocampal; Calcium Channel Blockers; Cyclic AMP Response Element-B | 2017 |
Nimodipine is more effective than nifedipine in attenuating morphine tolerance on chronic co-administration in the rat tail-flick test.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Disease Models, Animal; Dos | 2008 |
Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase.
Topics: Alcohol-Induced Disorders; Alcohols; Analysis of Variance; Animals; Body Weight; Brain; Calcium Chan | 2008 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Mod | 2009 |
Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Topics: Administration, Topical; Animals; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Dis | 2009 |
Experimental subarachnoid hemorrhage in the rat: influences of nimodipine.
Topics: Animals; Brain Injuries; Disease Models, Animal; Fibrinolytic Agents; Glial Fibrillary Acidic Protei | 2008 |
Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Topics: 3-Mercaptopropionic Acid; Analysis of Variance; Animals; Anticonvulsants; ATP Binding Cassette Trans | 2009 |
Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs.
Topics: Administration, Topical; Animals; Brain; Cerebrovascular Circulation; Disease Models, Animal; Male; | 2013 |
[Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm].
Topics: Animals; Disease Models, Animal; Female; Humans; Male; Nimodipine; Rabbits; Random Allocation; Tissu | 2009 |
The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model.
Topics: Animals; Basilar Artery; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; Injections, | 2009 |
Organophosphorus-induced delayed neuropathy: a simple and efficient therapeutic strategy.
Topics: Animals; Calcium; Calcium Channels; Calcium Gluconate; Carboxylic Ester Hydrolases; Chickens; Diseas | 2010 |
Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
Topics: Animals; Avoidance Learning; Behavior, Animal; Blood Pressure; Calcium Channel Blockers; Cerebrovasc | 2009 |
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium Channel Blockers; Cell Transplantation; Den | 2010 |
Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats.
Topics: Adenosine Triphosphatases; Animals; Brain; Brain Injuries; Chalcone; Disease Models, Animal; Malondi | 2010 |
Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Administration, Oral; Analysis of Variance; Angiography, Digital Subtraction; Animals; Basilar Arter | 2011 |
Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Analysis of Variance; Animals; Basilar Artery; Calcium Channel Blockers; Cilostazol; Disease Models, | 2011 |
Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Angiography, Digital Subtraction; Animals; Basilar Artery; Benzhydryl Compounds; Calcium Channel Blo | 2011 |
Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits.
Topics: Angiography, Digital Subtraction; Animals; Basilar Artery; Calcium Channel Blockers; Disease Models, | 2011 |
The effects of intrathecal nicergoline and nimodipine in cerebral vasospasm: an experimental study in rabbits.
Topics: Adrenergic alpha-Antagonists; Angiography, Digital Subtraction; Animals; Basilar Artery; Calcium Cha | 2011 |
[Changes of nitric oxide and endothelin-1 levels in rat brain tissue during cerebral vasospasm following subarachnoid hemorrhage and protective effect of nimodipine].
Topics: Animals; Brain; Cerebrovascular Circulation; Disease Models, Animal; Endothelin-1; Nimodipine; Nitri | 2001 |
[Effects of nimodipine on rabbits with symptomatic cerebral vasospasm].
Topics: Animals; Basilar Artery; Disease Models, Animal; Nimodipine; Rabbits; Vasodilator Agents; Vasospasm, | 2011 |
Synergistic protective effect of astragaloside IV-tetramethylpyrazine against cerebral ischemic-reperfusion injury induced by transient focal ischemia.
Topics: Animals; Astragalus Plant; Cardiovascular Agents; Caspase 3; Disease Models, Animal; Drug Synergism; | 2012 |
Nimodipine accelerates reinnervation of denervated rat thyroarytenoid muscle following nerve-muscle pedicle implantation.
Topics: Animals; Denervation; Disease Models, Animal; Electromyography; Female; Follow-Up Studies; Laryngeal | 2012 |
Cisternal sustained release dihydropyridines for subarachnoid hemorrhage.
Topics: Animals; Delayed-Action Preparations; Dihydropyridines; Disease Models, Animal; Dogs; Female; Macaca | 2012 |
Nimodipine attenuation of early brain dysfunctions is partially related to its inverting acute vasospasm in a cisterna magna subarachnoid hemorrhage (SAH) model in rats.
Topics: Animals; Blood-Brain Barrier; Cerebrovascular Circulation; Cisterna Magna; Disease Models, Animal; M | 2012 |
The impact of nimodipine administration combined with nerve-muscle pedicle implantation on long-term denervated rat thyroarytenoid muscle.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Female; Laryngeal Muscles; Muscle Denerva | 2013 |
The therapeutic effects of melatonin and nimodipine in rats after cerebral cortical injury.
Topics: Animals; Brain; Brain Edema; Brain Injuries; Disease Models, Animal; Drug Combinations; Lipid Peroxi | 2012 |
Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cardiotoxins; Clomipramine; Cyclophosphamide; Disease | 2014 |
Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms.
Topics: Alkaloids; Amino Acids; Animals; Anticonvulsants; Antioxidants; Atropine; Benzodioxoles; Biogenic Mo | 2013 |
Calmodulin kinase IV-dependent CREB activation is required for neuroprotection via NMDA receptor-PSD95 disruption.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Brain Infarction; Calcium Channel Blockers; Calcium-C | 2013 |
Effects of nimodipine on salicylate ototoxicity.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents, Non-Steroidal; Auditory Threshold; Blood Press | 2002 |
Nimodipine ameliorates trauma-induced cochlear neuronal death.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Signaling; Cell Death; Cochlear Nerve; Disease M | 2002 |
Effects of nimodipine on quinine ototoxicity.
Topics: Action Potentials; Animals; Audiometry; Auditory Threshold; Calcium Channel Blockers; Calcium Channe | 2003 |
The effects of calcium channel antagonist nimodipine on end-plate vascularity of the degenerated intervertebral disc in rats.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Female; Intervertebral Disc; Male; Nimodi | 2003 |
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Axons; Calcium Channel | 2003 |
Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen.
Topics: Adrenal Cortex Hormones; Animals; Antioxidants; Blood Flow Velocity; Calcium Channel Blockers; Cereb | 2003 |
Therapeutic effect of nimodipine on experimental brain injury.
Topics: Animals; Biopsy, Needle; Brain Edema; Brain Injuries; Calcium Channel Blockers; Disease Models, Anim | 2003 |
Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia.
Topics: Animals; Brain; Brain Ischemia; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signalin | 2004 |
Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Anabasine; Animals; Antipsychotic Agents; Disease Models, A | 2004 |
Potentiation of antihyperalgesic activity of diclofenac by nimodipine in a formalin model of facial pain in rats.
Topics: Animals; Calcium Channel Blockers; Diclofenac; Disease Models, Animal; Dose-Response Relationship, D | 2004 |
Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Brain Chemistry; Brain Ischemia; Calcium Chan | 2005 |
Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Brain; Brain Injuries; Calcium Channel Blockers; Cell | 2005 |
AD6, a coumarin derivative, and other pharmacological approaches to splanchnic artery occlusion (SAO) shock therapy.
Topics: Animals; Chromonar; Convulsive Therapy; Disease Models, Animal; Macrophages, Peritoneal; Male; Nimod | 1989 |
Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Brain Chemistry; Calcium Channel Blockers; Cerebral Hemorrhage; Cereb | 2006 |
[A simple and repeatable model of subarachnoid hemorrhage in rats].
Topics: Animals; Behavior, Animal; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2005 |
Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage.
Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Behavior, Animal; Calcium Channel Blockers; Dis | 2006 |
A comparative study on the individual and combined effects of baicalin and jasminoidin on focal cerebral ischemia-reperfusion injury.
Topics: Analysis of Variance; Animals; Brain; Brain Ischemia; Brain-Derived Neurotrophic Factor; Caspase 3; | 2006 |
Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model.
Topics: 3-Mercaptopropionic Acid; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, M | 2007 |
Intrathecal co-administration of morphine and nimodipine produces higher antinociceptive effect by synergistic interaction as evident by injecting different doses of each drug in rats.
Topics: Analgesics, Opioid; Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relatio | 2007 |
Neurophysiology: stressful pacemaking.
Topics: Animals; Antiparkinson Agents; Calcium; Calcium Channels, L-Type; Disease Models, Animal; Disease Pr | 2007 |
Calcium antagonism in neonatal rats with kaolin-induced hydrocephalus.
Topics: Animals; Animals, Newborn; Brain; Brain Damage, Chronic; Calcium Channel Blockers; Calcium Channels; | 2007 |
Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Aminobutyric | 2007 |
Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Dementia, Vascular; Disease Models, Animal; Dose-Res | 2008 |
Effects of intrarenal administration of the calcium antagonist nimodipine during porcine aortic occlusion-induced ischemia/reperfusion injury.
Topics: Animals; Aorta; Apoptosis; Calcium; Calcium Channel Blockers; Cyclin-Dependent Kinase Inhibitor p21; | 2008 |
Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia.
Topics: Animals; Blood Pressure; Brain Edema; Calcium Channel Blockers; Carotid Artery, External; Cerebral A | 1995 |
[Medical treatment of spinal cord injury during the acute phase. Effect of a calcium inhibitor].
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Nimodipine; Papio; Regional Blood Flow; S | 1993 |
Possibilities to evaluate and diminish the effects of the trauma in spinal cord lesions. An experimental study in the rat.
Topics: Animals; Disease Models, Animal; Evoked Potentials; Indomethacin; Naloxone; Neural Conduction; Nimod | 1994 |
Can nimodipine prevent ischaemic reperfusion injury in the rat brain?
Topics: Animals; Brain; Brain Ischemia; Disease Models, Animal; Evoked Potentials, Somatosensory; Nimodipine | 1993 |
Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat.
Topics: Animals; Autonomic Nervous System; Blood Glucose; Blood Pressure; Body Weight; Diabetic Neuropathies | 1994 |
Nimodipine after circulatory arrest: effects on oxygen delivery and consumption.
Topics: Animals; Blood Gas Analysis; Cardiopulmonary Resuscitation; Combined Modality Therapy; Disease Model | 1994 |
Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, D | 1995 |
The effects of gamma 2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Cerebral Arteries; Cerebral Cortex; Cerebrovascul | 1996 |
Nimodipine at a dose that slows ABR latencies does not protect the ear against noise.
Topics: Acoustic Stimulation; Administration, Oral; Analysis of Variance; Animals; Auditory Threshold; Calci | 1997 |
Effects of nimodipine on the cerebrovascular and neuronal changes during pneumococcal meningitis in the rat.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Neurons | 1997 |
Spontaneously hypertensive rats: a potential model to identify drugs for treatment of learning disorders.
Topics: Aging; Analysis of Variance; Animals; Blood Pressure; Calcium Channel Blockers; Cognition Disorders; | 1998 |
The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study.
Topics: Anesthetics, Local; Animals; Arrhythmias, Cardiac; Blood Pressure; Bupivacaine; Calcium Channel Bloc | 1998 |
Effect of intrathecal nimodipine on spinal cord blood flow and evoked potentials in the normal or injured cord.
Topics: Animals; Blood Pressure; Disease Models, Animal; Evoked Potentials; Injections, Spinal; Male; Nimodi | 1998 |
[The effect of nimodipine on a local ischemic brain lesion].
Topics: Animals; Brain Ischemia; Disease Models, Animal; Drug Evaluation, Preclinical; Microcirculation; Nim | 1998 |
Basic principles of cerebral protection in humans.
Topics: Adrenal Cortex Hormones; Anesthetics; Animals; Barbiturates; Blood Glucose; Blood Pressure; Body Tem | 1999 |
L-type calcium channel regulation of abnormal tyrosine hydroxylase expression in cerebella of tottering mice.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Calcium Chan | 1999 |
Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Diazepam; Disease Models, Animal; Drug Therapy, | 2000 |
Studies on a model of long term alcohol drinking.
Topics: Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Animals; Brain; Calcium; Calcium Channel | 2001 |
Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats.
Topics: Acute-Phase Reaction; Animals; Brain Injuries; Disease Models, Animal; Female; Free Radicals; Lipid | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; | 2001 |
Reversibility of nimodipine binding to brain in transient cerebral ischemia.
Topics: Animals; Binding Sites; Brain; Brain Chemistry; Disease Models, Animal; Ischemic Attack, Transient; | 1992 |
Vasospasm after experimentally induced subarachnoid haemorrhage and treatment with nimodipine.
Topics: Animals; Brain; Calcium; Disease Models, Animal; Endothelium, Vascular; Ischemic Attack, Transient; | 1992 |
Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine.
Topics: Animals; Blood Pressure; Calcium; Disease Models, Animal; Evoked Potentials, Somatosensory; Heart Ra | 1992 |
Quinine-induced tinnitus in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Nimodipin | 1991 |
Effect of nimodipine on ischemia-induced brain edema and mortality in a novel transient middle cerebral artery occlusion model.
Topics: Animals; Autoradiography; Brain Edema; Brain Ischemia; Calcium Radioisotopes; Cerebral Arteries; Dis | 1990 |
Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat.
Topics: Animals; Blood Pressure; Cell Survival; Coronary Disease; Disease Models, Animal; Electrocardiograph | 1990 |
Morphine withdrawal in cortical slices: suppression by Ca2+-channel inhibitors of abstinence-induced [3H]-noradrenaline release.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1988 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Evoked Potentials, Somatosensory; Heart Rate; Injec | 1989 |
An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage.
Topics: Acute Disease; Animals; Blood Pressure; Cerebrovascular Circulation; Disease Models, Animal; Evoked | 1989 |
Long-term neurological assessment of the post-resuscitative effects of flunarizine, verapamil and nimodipine in a new model of global complete ischaemia.
Topics: Anesthesia; Animals; Behavior, Animal; Disease Models, Animal; Electroencephalography; Electromyogra | 1989 |
Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats.
Topics: Animals; Behavior, Animal; Blood Pressure; Central Nervous System Diseases; Discrimination Learning; | 1988 |
The effect of nimodipine on intracranial pressure. Volume-pressure studies in a primate model.
Topics: Animals; Blood Pressure; Brain; Cerebrovascular Circulation; Cerebrovascular Disorders; Disease Mode | 1987 |
Cerebrovascular and metabolic changes during the delayed vasospasm following experimental subarachnoid hemorrhage in baboons, and treatment with a calcium antagonist.
Topics: Animals; Blood Flow Velocity; Cerebral Angiography; Cerebral Arteries; Disease Models, Animal; Femal | 1987 |
Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Dogs; Female; Injections | 1985 |
Chronic cerebral vasospasm: effect of calcium antagonists.
Topics: Animals; Cerebral Angiography; Chronic Disease; Disease Models, Animal; Dogs; Injections; Ischemic A | 1986 |
Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Female; Ischemic Attack, Transient; Macac | 1985 |